Bevacizumab: radiation combination produces restricted diffusion on brain MRI.
暂无分享,去创建一个
[1] J. Raizer,et al. Diffusion abnormalities of the corpus callosum in patients receiving bevacizumab for malignant brain tumors: suspected treatment toxicity , 2014, Journal of Neuro-Oncology.
[2] Helen D'Arceuil,et al. Probing tissue microstructure with restriction spectrum imaging: Histological and theoretical validation , 2013, Human brain mapping.
[3] T. Cloughesy,et al. Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls , 2012, American Journal of Neuroradiology.
[4] A G Sorensen,et al. Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma , 2011, American Journal of Neuroradiology.
[5] P. Gutin,et al. Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma , 2011, American Journal of Neuroradiology.
[6] Tracy T Batchelor,et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. , 2010, Neuro-oncology.
[7] M. Frosch,et al. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Hattingen,et al. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients , 2010, Journal of Neuro-Oncology.
[9] T. Mikkelsen,et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker , 2010, Journal of Neuro-Oncology.
[10] M. J. van den Bent,et al. Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.
[11] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Server,et al. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema , 2009, Acta radiologica.
[13] Matthew S. Brown,et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.
[14] A. Brandes,et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.
[15] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[16] Thomas L Chenevert,et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. , 2006, Magnetic resonance imaging.
[17] K. Kono,et al. The role of diffusion-weighted imaging in patients with brain tumors. , 2001, AJNR. American journal of neuroradiology.
[18] P Van Tassel,et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.
[19] Toshinori Hirai,et al. Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.